Limits...
Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases.

Li YY, Zhou C, Yang DX, Wang J, Liu ZJ, Wang XY, Li K - Cancer Biol Med (2015)

Bottom Line: Both groups failed to reach a statistical difference in DCR (100% vs. 86%, P=0.212).The median PFS and OS of the TEP/TCE group were slightly longer than those of the EP/CE group, although both groups failed to reach a statistical difference (10.5 vs. 8.9 months, P=0.484; 24.0 vs. 17.5 months, P=0.457).Both rates of grade IV bone marrow depression and termination of chemotherapy in the TEP/TCE group were significantly higher than those in the EP/CE group (26.3% vs. 7.0%, P=0.036; 31.6% vs. 14.7%, P=0.004).

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Diagnosis and Treatment Center, Tianjin 300060, China.

ABSTRACT

Objective: To compare the efficacy and adverse effects of paclitaxel-etoposide-carboplatin/cisplatin (TEP/TCE) regimen with those of etoposide-carboplatin/cisplatin (EP/CE) regimen as first-line treatment for combined small-cell lung cancer (CSCLC).

Methods: A retrospective study was conducted on 62 CSCLC patients who were treated at Tianjin Medical University Cancer Institute and Hospital from July 2000 to April 2013 and administered with TEP/TCE regimen (n=19) or EP/CE regimen (n=43) as first-line CSCLC treatment. All patients received more than two cycles of chemotherapy, and the response was evaluated every two cycles. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects.

Results: ORR between the TEP/TCE and EP/CE groups showed a statistical difference (90% vs. 53%, P=0.033). Both groups failed to reach a statistical difference in DCR (100% vs. 86%, P=0.212). The median PFS and OS of the TEP/TCE group were slightly longer than those of the EP/CE group, although both groups failed to reach a statistical difference (10.5 vs. 8.9 months, P=0.484; 24.0 vs. 17.5 months, P=0.457). However, stratified analysis indicated that the PFS of patients with stages III and IV CSCLC showed marginally significant difference between the TEP/TCE and EP/CE groups (19.5 vs. 7.6 months; P=0.071). Both rates of grade IV bone marrow depression and termination of chemotherapy in the TEP/TCE group were significantly higher than those in the EP/CE group (26.3% vs. 7.0%, P=0.036; 31.6% vs. 14.7%, P=0.004).

Conclusion: The TEP/TCE regimen may not be preferred for CSCLC, and this three-drug regimen requires further exploration and research. To date, the EP/CE regimen remains the standard treatment for CSCLC patients.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier curves for OS of 62 patients with stages I-IV CSCLC. The median OS of 3-drug group was not significantly longer than that of 2-drug group (24.0 vs. 17.5 months, P=0.457). OS, overall survival; CSCLC, combined small-cell lung cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493380&req=5

f2: Kaplan-Meier curves for OS of 62 patients with stages I-IV CSCLC. The median OS of 3-drug group was not significantly longer than that of 2-drug group (24.0 vs. 17.5 months, P=0.457). OS, overall survival; CSCLC, combined small-cell lung cancer.

Mentions: All patients were followed up until November 28, 2013, and the median follow-up time was 12.7 months (range, 2-73 months). A total of 30 patients were alive at the end of follow-up, which comprised 11 patients from the TEP/TCE group and 19 patients from the EP/CE group. The median PFS and OS of the TEP/TCE group were slightly longer than those of the EP/CE group, although both groups failed to reach a statistical difference (10.5 vs. 9.8 months, P=0.484, χ2=0.489; 24 vs. 17.5 months, P=0.457, χ2=0.554) (Figures 1,2). However, stratified analysis indicated that in patients with stages III and IV CSCLC, the median PFS nearly reached a statistical difference between the TEP/TCE and EP/CE groups (19.5 vs. 7.6 months, P=0.071, χ2=3.259), whereas the median OS failed to reach a statistical difference (22.8 vs. 14.3 months, P=0.269, χ2=1.224) (Figures 3,4). However, no significant difference existed between the two groups at stages I and II (Figures 5,6).


Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases.

Li YY, Zhou C, Yang DX, Wang J, Liu ZJ, Wang XY, Li K - Cancer Biol Med (2015)

Kaplan-Meier curves for OS of 62 patients with stages I-IV CSCLC. The median OS of 3-drug group was not significantly longer than that of 2-drug group (24.0 vs. 17.5 months, P=0.457). OS, overall survival; CSCLC, combined small-cell lung cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493380&req=5

f2: Kaplan-Meier curves for OS of 62 patients with stages I-IV CSCLC. The median OS of 3-drug group was not significantly longer than that of 2-drug group (24.0 vs. 17.5 months, P=0.457). OS, overall survival; CSCLC, combined small-cell lung cancer.
Mentions: All patients were followed up until November 28, 2013, and the median follow-up time was 12.7 months (range, 2-73 months). A total of 30 patients were alive at the end of follow-up, which comprised 11 patients from the TEP/TCE group and 19 patients from the EP/CE group. The median PFS and OS of the TEP/TCE group were slightly longer than those of the EP/CE group, although both groups failed to reach a statistical difference (10.5 vs. 9.8 months, P=0.484, χ2=0.489; 24 vs. 17.5 months, P=0.457, χ2=0.554) (Figures 1,2). However, stratified analysis indicated that in patients with stages III and IV CSCLC, the median PFS nearly reached a statistical difference between the TEP/TCE and EP/CE groups (19.5 vs. 7.6 months, P=0.071, χ2=3.259), whereas the median OS failed to reach a statistical difference (22.8 vs. 14.3 months, P=0.269, χ2=1.224) (Figures 3,4). However, no significant difference existed between the two groups at stages I and II (Figures 5,6).

Bottom Line: Both groups failed to reach a statistical difference in DCR (100% vs. 86%, P=0.212).The median PFS and OS of the TEP/TCE group were slightly longer than those of the EP/CE group, although both groups failed to reach a statistical difference (10.5 vs. 8.9 months, P=0.484; 24.0 vs. 17.5 months, P=0.457).Both rates of grade IV bone marrow depression and termination of chemotherapy in the TEP/TCE group were significantly higher than those in the EP/CE group (26.3% vs. 7.0%, P=0.036; 31.6% vs. 14.7%, P=0.004).

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Diagnosis and Treatment Center, Tianjin 300060, China.

ABSTRACT

Objective: To compare the efficacy and adverse effects of paclitaxel-etoposide-carboplatin/cisplatin (TEP/TCE) regimen with those of etoposide-carboplatin/cisplatin (EP/CE) regimen as first-line treatment for combined small-cell lung cancer (CSCLC).

Methods: A retrospective study was conducted on 62 CSCLC patients who were treated at Tianjin Medical University Cancer Institute and Hospital from July 2000 to April 2013 and administered with TEP/TCE regimen (n=19) or EP/CE regimen (n=43) as first-line CSCLC treatment. All patients received more than two cycles of chemotherapy, and the response was evaluated every two cycles. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects.

Results: ORR between the TEP/TCE and EP/CE groups showed a statistical difference (90% vs. 53%, P=0.033). Both groups failed to reach a statistical difference in DCR (100% vs. 86%, P=0.212). The median PFS and OS of the TEP/TCE group were slightly longer than those of the EP/CE group, although both groups failed to reach a statistical difference (10.5 vs. 8.9 months, P=0.484; 24.0 vs. 17.5 months, P=0.457). However, stratified analysis indicated that the PFS of patients with stages III and IV CSCLC showed marginally significant difference between the TEP/TCE and EP/CE groups (19.5 vs. 7.6 months; P=0.071). Both rates of grade IV bone marrow depression and termination of chemotherapy in the TEP/TCE group were significantly higher than those in the EP/CE group (26.3% vs. 7.0%, P=0.036; 31.6% vs. 14.7%, P=0.004).

Conclusion: The TEP/TCE regimen may not be preferred for CSCLC, and this three-drug regimen requires further exploration and research. To date, the EP/CE regimen remains the standard treatment for CSCLC patients.

No MeSH data available.


Related in: MedlinePlus